Gastroenterology
Volume 123, Issue 5 , Pages 1705-1725 , November 2002

AGA technical review on nonalcoholic fatty liver disease

References 

  1. American Gastroenterological Association . Position and policy statement: policy statement on the use of medical practice guidelines by managed care organizations and insurance carriers. Gastroenterology. 1995;108:925–926
  2. Gross PA, Barrett TL, Dellinger EP, Krause PJ, Martone WJ, McGowan JE, et al. Purpose of quality standards for infectious diseases. Infectious Diseases Society of America. Clin Infect Dis. 1994;18:421
  3. NHS center for reviews and dissemination . undertaking systematic reviews of research on effectiveness: CRD guidelines for those carrying out or commissioning reviews. CRD report #4. York: University of York; 1996;
  4. Zelman S. The liver in obesity. Arch Intern Med. 1958;90:141–156
  5. Payne JH, Dewind LT, Commons RR. Metabolic observations in patients with jejunocolic shunts. Am J Surg. 1963;106:273–289
  6. Catlin R. Liver dysfunction after intestinal bypass. JAMA. 1963;185:1693–1694
  7. McGill DB, Humpherys SR, Baggenstoss AH, Dickson ER. Cirrhosis and death after jejunoileal shunt. Gastroenterology. 1972;63:872–877
  8. Peters RL, Gay T, Reynolds TB. Post-jejuno-ileal bypass hepatic disease. Its similarity to alcoholic liver disease. Am J Clin Pathol. 1975;63:318–331
  9. Adler M, Schaffner F. Fatty liver hepatitis and cirrhosis in obese patients. Am J Med. 1979;67:811–816
  10. Thaler H. Relation of steatosis to cirrhosis. Clin Gastroenterol. 1975;4:273–280
  11. Nasrallah SM, Wills CE, Galambos JT. Hepatic morphology in obesity. Dig Dis Sci. 1981;26:325–327
  12. Itoh S, Tsukada Y, Motomura Y, Ichinoe A. Five patients with nonalcoholic diabetic cirrhosis. Acta Hepatogastroenterol Stuttg. 1979;26:90–97
  13. Falchuk KR, Fiske SC, Haggitt RC, Federman M, Trey C. Pericentral hepatic fibrosis and intracellular hyalin in diabetes mellitus. Gastroenterology. 1980;78:535–541
  14. Hornboll P, Olsen TS. Fatty changes in the liver: the relation to age, overweight and diabetes mellitus. Acta Pathol Microbiol Immunol Scand A. 1982;90:199–205
  15. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434–438
  16. Baker AL. Nonalcoholic steatonecrosis: a unique histopathologic lesion of the liver with multiple causes. Surv Dig Dis. 1985;3:154–164
  17. French SW, Eidus LB, Freeman J. Nonalcoholic fatty hepatitis: an important clinical condition. Can J Gastroenterol. 1989;3:189–197
  18. Lee RG. Nonalcoholic steatohepatitis: tightening the morphological screws on a hepatic rambler. Hepatology. 1995;21:1742–1743
  19. Galambos JT, Wills CE. Relationship between 505 paired liver tests and biopsies in 242 obese patients. Gastroenterology. 1978;74:1191–1195
  20. Nagore N, Scheur PJ. The pathology of diabetic hepatitis. J Pathol. 1988;156:155–160
  21. Hall PD. Pathological spectrum of alcoholic liver disease. Alcohol Alcohol Suppl. 1994;2:303–313
  22. Bacon BR, Farahvash MJ, Janney CG, Neuschwander Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994;107:1103–1109
  23. Christoffersen P, Petersen P. Morphological features in non-cirrhotic livers from patients with chronic alcoholism, diabetes mellitus or adipositas. A comparative study. Acta Pathol Microbiol Scand A. 1978;86A:495–498
  24. Gluud C, Christoffersen P, Andersen T, Morton JA, McGee JO. Occurrence and significance of Mallory bodies in morbidly obese patients. An immunohistochemical study. Acta Pathol Microbiol Immunol Scand A. 1984;92:39–43
  25. Younossi ZM, Boparai N. Agreement in pathologic interpretation of liver biopsy specimens in posttransplant hepatitis C infection. Arch Pathol Lab Med. 1999;123:143–145
  26. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–1419
  27. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–2474
  28. Anderson T, Christoffersen P, Gluud C. The liver in consecutive patients with morbid obesity: a clinical morphological and biochemical study. Int J Obes. 1984;8:107–115
  29. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology. 1995;22:1714–1719
  30. Franzese A, Vajro P, Argenziano A, Puzziello A, Iannucci MP, Saviano MC, et al. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci. 1997;42:1428–1432
  31. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med. 1988;27:142–149
  32. Kawasaki T, Hashimoto N, Kikuchi T, Takahashi H, Uchiyama M. The relationship between fatty liver and hyperinsulinemia in obese Japanese children. J Pediatr Gastroenterol Nutr. 1997;24:317–321
  33. Tazawa Y, Noguchi H, Nishinomiya F, Takada G. Serum alanine aminotransferase activity in obese children. Acta Paediatr. 1997;86:238–241
  34. Ikai E, Ishizaki M, Suzuki Y, Ishida M, Noborizaka Y, Yamada Y. Association between hepatic steatosis, insulin resistance and hyperinsulinaemia as related to hypertension in alcohol consumers and obese people. J Hum Hypertens. 1995;9:101–105
  35. Marcos A, Fisher RA, Ham JM, Olzinski AT, Shiffman ML, Sanyal AJ, et al. Selection and outcome of living donors for adult to adult right lobe transplantation. Transplantation. 2000;69:2410–2415
  36. Ground KEV. Prevalence of fatty liver in healthy adults accidentally killed. Aviat Space Environ Med. 1984;55:59–61
  37. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology. 1990;11:74–80
  38. Tominaga K, Kurata JH, Chen YK, Fujimoto E, Miyagawa S, Abe I, et al. Prevalence of fatty liver in Japanese children and relationship to obesity. An epidemiological ultrasonographic survey. Dig Dis Sci. 1995;40:2002–2009
  39. Noguchi H, Tazawa Y, Nishinomiya F, Takada G. The relationship between serum transaminase activities and fatty liver in children with simple obesity. Acta Paediatr Jpn. 1995;37:621–625
  40. Nomura F, Ohnishi K, Satomura Y. Liver function in moderate obesity: study in 535 moderately obese subjects among 4613 male company employees. Int J Obes. 1986;10:349–354
  41. Anderson T, Gluud C. Liver morphology in morbid obesity: a literature study. Int J Obes. 1984;8:97–106
  42. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000;132:112–117
  43. Kinugasa A, Tsunamoto K, Furukawa N, Sawada T, Kusunoki T, Shimada N. Fatty liver and its fibrous changes found in simple obesity of children. J Pediatr Gastroenterol Nutr. 1984;3:408–414
  44. Popkin BM, Udry JR. Adolescent obesity increases significantly in second and third generation U.S. immigrants: the National Longitudinal Study of Adolescent Health. J Nutr. 1998;128:701–706
  45. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord. 1998;22:39–47
  46. Johnson-Down L, O'Loughlin J, Koski KG, Gray-Donald K. High prevalence of obesity in low income and multiethnic schoolchildren: a diet and physical activity assessment. J Nutr. 1997;127:2310–2315
  47. Baldridge AD, Perez-Atayde AR, Graeme-Cook F, Higgins L, Lavine JE. Idiopathic steatohepatitis in childhood: a multicenter retrospective study. J Pediatr. 1995;127:700–704
  48. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11:74–80
  49. Diehl AM, Goodman Z, Ishak KG. Alcoholic liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology. 1988;95:1056–1062
  50. Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol. 1989;20:594–598
  51. Nonomura A, Mizukami Y, Unoura M, Kobayashi K, Takeda Y, Takeda R. Clinicopathologic study of alcohol-like liver disease in non-alcoholics; non-alcoholic steatohepatitis and fibrosis. Gastroenterol Jpn. 1992;27:521–528
  52. Lee JH, Doe J. Familial risk ratios for extreme obesity: implications for mapping human obesity genes. Int J Obes Relat Metab Discord. 1997;21:935–940
  53. Trevisan R. The epidemiology of diabetes mellitus. Nephrol Dial Transplant. 1998;13(Suppl):2–5
  54. Chagnon YC. Familial aggregation of obesity, candidate genes and quantitative trait loci. Curr Opin Lipidol. 1997;8:205–211
  55. Struben VM, Hespenheide EE, Caldwell SH. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med. 2000;108:9–13
  56. Altman AR, Gottfried EB, Paronetto F, Lieber CS. Idiopathic familial cirrhosis and steatosis in adults. Gastroenterology. 1979;77:1211–1216
  57. Castellano G, Garfia C, Gomez-Coronado D, Arenas J, Manzanares J, Colina F, et al. Diffuse fatty liver in familial heterozygous hypobetalipoproteinemia. J Clin Gastroenterol. 1997;25:379–382
  58. Ogatta H, Akagi K, Nagamatsu A, Suzuki N, Nomiyama K, Fujishima M. Fatty liver in a case with heterozygous familial hypobetalipoproteinemia. Am J Gastroenterol. 1997;92:339–342
  59. Kagimoto T, Higaki T, Nagata K, Morino Y, Takatsuki K. An interesting syndrome of hemolytic anemia, degeneration of the liver and diabetes associated with a high red cell Mg-ATPase, detected by 31P spectroscopy. NMR Biomed. 1989;2:93–97
  60. Hsieh SD, Yoshinaga H, Muto T, Sakurai Y. Regular physical activity and coronary risk factors in Japanese men. Circulation. 1998;97:661–665
  61. Ikai E, Honda R, Yamada Y. Serum gamma-glutamyl transpeptidase level and blood pressure in nondrinkers: a possible pathogenetic role of fatty liver in obesity-related hypertension. J Hum Hypertens. 1994;8:95–100
  62. Maruhama Y, Abe R, Okuguchi F, Oikawa S, Ohneda A, Goto Y. Interactions of obesity and glucose-stimulated insulin secretion in familial hypertriglyceridemia. Diabetes. 1978;27:682–693
  63. Lonardo A. Fatty liver and nonalcoholic steatohepatitis. Where do we stand and where are we going?. Dig Dis. 1999;17:80–89
  64. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107:450–455
  65. Lyznicki JM, Young DC, Riggs JA, Davis RM, Council on Scientific Affairs, American Medical Association . Obesity: assessment and management in primary care. Am Fam Physician. 2001;63:2185–2196
  66. Ludwig J, McGill DB, Lindor KD. Nonalcoholic steatohepatitis. J Gastroenterol Hepatol. 1997;12:398–403
  67. Luyckx FH, Desaive C, Thiry A, Dewe W, Scheen AJ, Gielen JE, et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord. 1998;22:222–226
  68. Ranlov I, Hardt F. Regression of liver steatosis following gastroplasty or gastric bypass for morbid obesity. Digestion. 1990;47:208–214
  69. Park HS, Kim MW, Shin ES. Effect of weight control on hepatic abnormalities in obese patients with fatty liver. J Korean Med Sci. 1995;10:414–421
  70. Eriksson S, Eriksson KF, Bondesson L. Nonalcoholic steatohepatitis in obesity: a reversible condition. Acta Med Scand. 1986;220:83–88
  71. Kral JG, Schaffner F, Pierson RN, Wang J. Body fat topography as an independent predictor of fatty liver. Metabolism. 1993;42:548–551
  72. Gillum RF, Mussolino ME, Madans JH. Body fat distribution and hypertension incidence in women and men. The NHANES I Epidemiologic Follow-up Study. Int J Obes Relat Metab Disord. 1998;22:127–134
  73. Van Steenbergen W, Lanckmans S. Liver disturbances in obesity and diabetes mellitus. Int J Obes Relat Metab Disord. 1995;19(Suppl 3):S27–S36
  74. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerothic cardiovascular disease. Diabetes Care. 1991;14:173–194
  75. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30:1356–1362
  76. Goto T, Onuma T, Takebe K, Kral JG. The influence of fatty liver on insulin clearance and insulin resistance in non-diabetic Japanese subjects. Int J Obes Relat Metab Disord. 1995;19:841–845
  77. Inokuchi T, Watanabe K, Kameyama H, Orita M. Altered basal C-peptide/insulin molar ratios in obese patients with fatty liver. Jpn J Med. 1988;27:272–276
  78. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001;120:1183–1192
  79. Caldwell SH, Swerdlow RH, Khan EM, Iezzoni JC, Hespenheide EE, Parks JK, et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol. 1999;31:430–434
  80. Weltman MD, Farrell GC, Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology. 1996;111:1645–1653
  81. Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A. 1997;94:2557–2562
  82. Partin JS, Partin JC, Schubert WK, McAdams AJ. Liver ultrastructure in abetalipoproteinemia: evolution of micronodular cirrhosis. Gastroenterology. 1974;67:107–118
  83. Powell EE, Searle J, Mortimer R. Steatohepatitis associated with limb lipodystrophy. Gastroenterology. 1989;97:1022–1024
  84. Shah SS, Desai HG. Apolipoprotein deficiency and chronic liver disease. J Assoc Phys India. 2001;49:274–278
  85. Robertson DA, Wright R. Cirrhosis in partial lipodystrophy. Postgrad Med J. 1989;65:318–320
  86. Cauble MS, Gilroy R, Sorrell MF, Mailliard ME, Sudan DL, Anderson JC, et al. Lipoatrophic diabetes and end-stage liver disease secondary to nonalcoholic steatohepatitis with recurrence after liver transplantation. Transplantation. 2001;71:892–895
  87. Wasserman JM, Thung SN, Berman R, Bodenheimer HC, Sigal SH. Hepatic Weber-Christian disease. Semin Liv Dis. 2001;21:115–118
  88. Poucell S, Ireton J, Valencia-Mayoral P, Downar E, Larratt L, Patterson J. Amiodarone-associated phospholipidosis and fibrosis of the liver. Light, immunohistochemical and electron microscopic studies. Gastroenterology. 1984;86:926–936
  89. Pessayre D, Bichara M, Degott C, Potet F, Benhamou JP, Feldman G. Perhexiline maleate induced cirrhosis. Gastroenterology. 1979;76:170–177
  90. Pratt DS, Knox TA, Erban J. Tamoxifen-induced steatohepatitis. Ann Intern Med. 1995;123:236
  91. Martinez E, Mocroft A, Garcia-Viejo MA, Perez-Cuevas JB, Blanco JL. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001;357:592–598
  92. Kotler DP, Engleson ES. The lowdown on lipodystrophy. Special report from the 2nd international workshop on adverse drug reactions and lipodystrophy. Posit Living. 2001;10:5–6
  93. Rakotoambinina B, Medioni J, Rabian C, Jubault V, Jais JP, Viard JP. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1 infected patients receiving triple combination antiretroviral therapy with a protease inhibitor. J Acquir Immune Defic Syndr. 2001;27:443–449
  94. Herman JS, Easterbrook PJ. The metabolic toxicities of antiretroviral therapies. Int J STD AIDS. 2001;12:555–562
  95. Van der valk M, Bisschop PH, Romjin JA, Ackermans MT, Lange JM. Lipodystrophy in HIV-1 positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS. 2001;15:2093–2100
  96. Cotrim HP, Andrade ZA, Parana R, Portugal M, Lyra LG, Freitas LA. Nonalcoholic steatohepatitis: a toxic liver disease in industrial workers [see comments]. Liver. 1999;19:299–304
  97. George DK, Goldwurm S, MacDonald GA, Cowley LL, Walker NI, Ward PJ, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology. 1998;114:311–318
  98. Bonkovsky HL, Jawaid Q, Tortorelli K, LeClair P, Cobb J, Lambrecht RW, et al. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol. 1999;31:421–429
  99. Younossi ZM, Gramlich T, Bacon BR, Matteoni CA, Boparai N, O'Neill R, et al. Hepatic iron and nonalcoholic fatty liver disease. Hepatology. 1999;30:847–850
  100. Sonsuz A, Basaranoglu M, Ozbay G. Relationship between aminotransferase levels and histopathological findings in patients with nonalcoholic steatohepatitis (letter). Am J Gastroenterol. 2000;95:1370–1371
  101. Itoh S, Yougel T, Kawagoe K. Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis. Am J Gastroenterol. 1987;82:650–654
  102. Tajiri K, Takenawa H, Yamaoka K, Yamane M, Marumo F, Sato C. Nonalcoholic steatohepatitis masquerading as autoimmune hepatitis. J Clin Gastroenterol. 1997;25:538–540
  103. da Silva PM, Eliseu T, Costa MM, Bastos H, Nobre FL. Nonalcoholic steatohepatitis. Acta Med Port. 1995;8:323–327
  104. Sanson-Fisher R. The measurement of alcohol consumption and alcohol-related problems. Aust Drug Alcohol Rev. 1986;5:309–310
  105. Lewis KO, Paton A. Tools of alcohol detection. Br Med J. 1981;283:1531–1532
  106. Salaspuro M. Use of enzymes for the diagnosis of alcohol-related organ damage. Enzyme. 1987;37:87–107
  107. Nalpas B, Vassault A, Charpin S, Lacour B, Berthelot P. Serum mitochondrial aspartate aminotransferase: a sensitive marker of alcoholism with or without alcoholic hepatitis. Hepatology. 1984;4:893–896
  108. Nalpas B, Vassault A, Charpin S, Lacour B, Berthelot P. Serum mitochondrial aspartate aminotransferase as a marker of chronic alcoholism: diagnostic value and interpretation in a liver unit. Hepatology. 1986;6:608–614
  109. Storey E, Anderson GJ, Mack U, Powell LJ, Halliday JW. Desialylated transferrin as a serologic marker of chronic excessive alcohol ingestion. Lancet. 1987;1:1292–1294
  110. Fletcher LM, Kwoh Gain I, Powell EE, Powell LW, Halliday JW. Markers of chronic alcohol ingestion in patients with nonalcoholic steatohepatitis: an aid to diagnosis. Hepatology. 1991;13:455–459
  111. Nomura F, Ohnishi K, Koen H, Hiyama Y, Nakayama T, Itoh Y, et al. Serum cholinesterase in patients with fatty liver. J Clin Gastroenterol. 1986;8:599–602
  112. Ong JP, Younossi ZM, Speer C, Olano A, Gramlich T, Boparai N. Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver. 2001;21:266–271
  113. Gore RM. Diffuse liver disease. In:  Gore RM,  Levine MS,  Laufer I editor. Textbook of gastrointestinal radiology. Philadelphia: Saunders; 1994;p. 1968–2017
  114. Yajima Y, Ohta K, Narui T, Abe R, Suzuki H, Ohtsuki M. Ultrasonographical diagnosis of fatty liver: significance of the liver-kidney contrast. Tohoku J Exp Med. 1983;139:43–50
  115. Fusamoto H, Suzuki K, Hayashi N, et al.  Obesity and liver disease: evaluation of fatty infiltration of the liver using ultrasonic attenuation. J Nutr Sci Vitaminol Tokyo. 1991;37(suppl):S71–S77
  116. Kreft B, Tanimoto A, Baba Y, Zhao L, Chen J, Middleton MA, et al. Diagnosis of fatty liver with MR imaging. J Magn Reson Imaging. 1992;2:463–471
  117. Yousefzadeh D, Lupetin AR, Jackson JH. The radiographic signs of fatty liver. Radiology. 1979;131:351–355
  118. Bydder GM, Chapman RWG, Harry D. Computed tomography attenuation values in fatty liver. Comput Tomograph. 1981;5:33–38
  119. Piekarski J, Goldberg HI, Royal SA, Axel L, Moss AA. Difference between liver and spleen CT numbers in the normal adult: its usefulness in predicting the presence of diffuse liver disease. Radiology. 1980;137:727–729
  120. Ducommun JC, Goldberg HI, Korobkin M, Moss AA, Kressel HY. The relation of liver fat to computed tomography numbers: a preliminary experimental study in rabbits. Radiology. 1979;130:511–513
  121. Galambos JT. Natural history of alcoholic hepatitis. 3. Histologic changes. Gastroenterology. 1972;63:1026–1035
  122. Jacobs JE, Birnbaum BA, Shapiro MA, Langlotz CP, Slosman F, Rubesin SE, et al. Diagnostic criteria for fatty infiltration of the liver on contrast-enhanced helical CT. AJR. 1998;171:659–664
  123. Johnston RJ, Stamm ER, Lewin JM, Hendrick RE, Archer PG. Diagnosis of fatty infiltration of the liver on contrast enhanced CT: limitations of liver-minus-spleen attenuation difference measurements. Abdom Imaging. 1998;23:409–415
  124. Mendler MH, Bouillet P, Le Sidaner A, Lavoine E, Labrousse F, Sautereau D, et al. Dual-energy CT in the diagnosis and quantification of fatty liver: limited clinical value in comparison to ultrasound scan and single-energy CT, with special reference to iron overload. J Hepatol. 1998;28:785–794
  125. Nomura F, Ohnishi K, Ochiai T, Okuda K. Obesity-related nonalcoholic fatty liver: CT features and follow-up studies after low-calorie diet. Radiology. 1987;162:845–847
  126. Outwater EK, Blasbalg R, Siegelman ES, Vala M. Detection of lipid in abdominal tissues with opposed-phase gradient echo images at 1.5 T: techniques and diagnostic importance. Radiographics. 1998;18:1465–1480
  127. Longo R, Pollesello P, Ricci C, Masutti F, Kvam BJ, Bercich L, et al  Proton MR spectroscopy in quantitative in vivo determination of fat content in human steatosis. J Magn Reson Imaging. 1995;5:281–285
  128. Fishbein MH, Gardner KG, Potter CJ, Schmalbrock P, Smith MA. Introduction of fast MR imaging in the assessment of hepatic steatosis. Magn Reson Imaging. 1997;15:287–293
  129. Marks DB, Marks AD, Smith CM. Generation of ATP from fatty acids and ketone bodies. In:  Marks DB,  Marks AD,  Smith CM editor. Basic medical biochemistry. Baltimore: Williams and Wilkins; 1996;p. 357–372
  130. Fishbein M, Smith M, Li BU. A rapid MRI technique for the assessment of hepatic steatosis in a subject with medium-chain acyl-coenzyme A dehydrogenase (MCAD) deficiency. J Pediatr Gastroenterol Nutr. 1998;27:224–227
  131. Chevallier P, Bahadoran P, Buckley MJ, Hebuterne X, Diaine B, Chevallier A, et al. Hepatic multi-nodular focal fatty metamorphosis in acquired porphyria cutanea tarda. Sonographic, CT, and MRI features. Clin Imaging. 1998;22:418–421
  132. Marks SJ, Moore NR, Ryley NG, Clark ML, Pointon JJ, Strauss BJ, et al. Measurement of liver fat by MRI and its reduction by dexfenfluramine in NIDDM. Int J Obes Relat Metab Disord. 1997;21:274–279
  133. Fishbein MH, Stevens WR. Rapid MRI using a modified Dixon technique: a noninvasive and effective method for detection and monitoring of fatty metamorphosis of the liver. Pediatr Radiol. 2001;31:806–809
  134. Van Ness MM, Diehl AM. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes?. Ann Intern Med. 1989;111:473–478
  135. Sorbi D, McGill DB, Thistle JL, Therneau TM, Henry J, Lindor KD. An assessment of the role of liver biopsies in asymptomatic patients with chronic liver test abnormalities. Am J Gastroenterol. 2000;95:3206–3210
  136. Itoh S, Yougel T, Kawagoe K. Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis. Am J Gastroenterol. 1987;82:650–654
  137. Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol. 1999;94:1018–1022
  138. Pinto HC, Baptista A, Camilo ME, Valente A, Saragoca A, de Moura MC. Nonalcoholic steatohepatitis. Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci. 1996;41:172–179
  139. Braillon A, Capron JP, Herve MA, Degott C, Quenum C. Liver in obesity. Gut. 1985;26:133–139
  140. Iturriaga H, Bunout D, Hirsch S, Ugarte G. Overweight as a risk factor or a predictive sign of histological liver damage in alcoholics. Am J Clin Nutr. 1988;47:235–238
  141. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. 1999;29:664–669
  142. Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology. 2000;32:689–692
  143. Contos MJ, Cales W, Sterling RK, Luketic VA, Shiffman ML, Mills AS, et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl. 2001;7:363–373
  144. Drenick EJ, Fisler J, Johnson D. Hepatic steatosis after intestinal bypass—prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition. Gastroenterology. 1982;82:535–548
  145. Drenick EJ, Simmons F, Murphy J. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small bowel bypass. N Engl J Med. 1970;282:829–834
  146. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001;121:91–100
  147. Adler M, Schaffner F. Fatty liver hepatitis and cirrhosis in obese patients. Am J Med. 1979;67:811–816
  148. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol induced steatohepatitis: a pilot study. Hepatology. 1996;23:1464–1467
  149. Hilden M, Juhl E, Thomen AC, Christoffersen P. Fatty liver persisting for up to 33 years. Acta Med Scand. 1973;194:485–489
  150. Propst A, Propst T, Judmaier G, Vogel W. Prognosis in nonalcoholic steatohepatitis (letter). Gastroenterology. 1995;108:1607
  151. Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol. 1997;27:103–107
  152. Vajro P, Fontanella A, Perna C, Orso G, Tedesco M, De Vincenzo A. Persistent hyperaminotransferasemia resolving after weight reduction in obese children [see comments]. J Pediatr. 1994;125:239–241
  153. Dean RH, Scott HW, Shull HJ, Gluck FW. Morbid obesity: problems associated with operative management. Am J Clin Nutr. 1977;30:90–97
  154. Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol. 1991;12:224–229
  155. Rashid M, Roberts EA. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr. 2000;30:48–53
  156. Ogden CL, Troiano RP, Briefel RR, Kuczmarski RJ, Flegal KM, Johnson CL. Prevalence of overweight among preschool children in the United States, 1971 through 1994. Pediatrics. 1997;99:E1
  157. Rosner B, Prineas R, Loggie J, Daniels SR. Percentiles for body mass index in U.S. children 5 to 17 years of age [see comments]. J Pediatr. 1998;132:211–222
  158. Moran JR, Ghishan FK, Halter SA, Greene HL. Steatohepatitis in obese children: a cause of chronic liver dysfunction. Am J Gastroenterol. 1983;78:374–377
  159. Snodgrass PJ. Obesity, small-bowel bypass and liver disease. N Engl J Med. 1970;282:870–871
  160. Kern WH, Heger AH, Payne JH, Dewind LT. Fatty metamorphosis of the liver in morbid obesity. Arch Pathol. 1973;96:342–346
  161. Kern WH, Payne JH, Dewind LT. Hepatic changes after small-intestinal bypass for morbid obesity. Am J Clin Pathol. 1974;61:763–768
  162. Salmon PA, Reedyk L. Fatty metamorphosis in patients with jejunoileal bypass. Surg Gynecol Obstet. 1975;141:75–84
  163. Petersen P. Fatty liver in patients with moderate alcohol consumption, diabetes mellitus and overweight. Scand J Gastroenterol. 1977;12:781–784
  164. Manes JL, Taylor HB, Starkloff GB. Relationship between hepatic morphology and clinical and biochemical findings in morbidly obese patients. J Clin Pathol. 1973;26:776–783
  165. White JJ, Moxley RT, Pozefsky T, Lockwood DH. Transient kwaskiorkor: a cause of fatty liver following small bowel bypass. Surgery. 1974;75:829–840
  166. Halloran LG, Hutcher NE, Levinson SA, Schatzki PF, Hume DM. Morphology of the liver before and after intestinal bypass for morbid obesity. Surg Forum. 1974;25:359–361
  167. Marubbio AT. Buchwald H, Schwartz MZ, Varco R. Hepatic lesions of central pericellular fibrosis in morbid obesity, and after jejunoileal bypass. Am J Clin Pathol. 1976;66:684–691
  168. Baddeley RM. Results of jejuno-ileostomy for gross refractory obesity. Br J Surg. 1976;63:801–806
  169. Nasrallah SM, Wills CE, Galambos JT. Liver injury following jejunoileal bypass. Are there markers?. Ann Surg. 1980;192:726–729
  170. Heimburger SL, Steiger E, Lo Gerfo P, Biehl AG, Williams MJ. Reversal of severe fatty hepatic infiltration after intestinal bypass for morbid obesity by calorie-free amino acid infusion. Am J Surg. 1975;129:229–235
  171. Griffen WO, Young VL, Stevenson CC. A prospective comparison of gastric and jejunoileal bypass procedures for morbid obesity. Ann Surg. 1977;186:500–509
  172. Buckwalter JA. Clinical trial of jejunoileal and gastric bypass for the treatment of morbid obesity: four-year progress report. Am Surg. 1980;46:377–381
  173. Luyckx FH, Scheen AJ, Desaive C, Thiry A, Lefebvre PJ. Parallel reversibility of biological markers of the metabolic syndrome and liver steatosis after gastroplasty-induced weight loss in severe obesity (letter). J Clin Endocrinol Metab. 1999;84:4293
  174. Lieverse RJ, Jansen JB, Masclee AA, Lamers CB. Gastrointestinal disturbances with obesity. Scand J Gastroenterol Suppl. 1993;200:53–58
  175. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Ikematsu H, Noguchi A, et al. Prevalence of gallstone disease in a general population of Okinawa, Japan [see comments]. Am J Epidemiol. 1988;128:598–605
  176. Araujo LM, De Oliveira DA, Nunes DS. Liver and biliary ultrasonography in diabetic and non-diabetic obese women. Diabetes Metab. 1998;24:458–462
  177. Moore SJ, Auchterlonie IA, Cole GF, Gray ES, Dean JC. Partial lipodystrophy presenting with myopathy. Dev Med Child Neurol. 1999;41:127–131
  178. Hubler A, Abendroth K, Keiner T, Stocker W, Kauf E, Hein G, et al. Dysregulation of insulin-like growth factors in a case of generalized acquired lipoatrophic diabetes mellitus (Lawrence Syndrome) connected with autoantibodies against adipocyte membranes. Exp Clin Endocrinol Diabetes. 1998;106:79–84
  179. Ursich MJ, Fukui RT, Galvao MS, Marcondes JA, Santomauro AT, Silva ME, et al. Insulin resistance in limb and trunk partial lipodystrophy (type 2 Kobberling-Dunnigan syndrome). Metabolism. 1997;46:159–163
  180. Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology. 1999;29:1215–1219
  181. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 2001;33:1358–1364
  182. Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Male PJ, Mentha G, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol. 2000;33:106–115
  183. Rubbia-Brandt L, Leandro G, Spahr L, Giostra E, Quadri R, Male PJ, et al. Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3. Histopathology. 2001;39:119–124
  184. Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, Matsuura Y, et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol. 1997;78:1527–1531
  185. Fujie H, Yotsuyanagi H, Moriya K, Shintani Y, Tsutsumi T, Takayama T, et al. Steatosis and intrahepatic hepatitis C virus in chronic hepatitis. J Med Virol. 1999;59:141–145
  186. Fernandez-Miranda C, Castellano G, Guijarro C, Fernandez I, Schoebel N, Larumbe S, et al. Lipoprotein changes in patients with hepatitis C treated with interferon alpha. Am J Gastroenterol. 1998;93:1901–1904
  187. Alexandropoulos EC, Kontochristopoulos GJ, Zakapoulou N. Hypertriglyceridemia during low-dose interferon alpha-2b treatment in a patient with Kaposi's sarcoma. Dermatology. 2001;202:344–345
  188. Garcia Urena MA, Colina Ruiz-Delgado F, Moreno Gonzalez E, Jimenez Romero C, Garcia Garcia I, Loinzaz Segurola C, et al. Hepatic steatosis in liver transplant donors: common feature of donor population?. World J Surg. 1998;22:837–844
  189. Broughan TA, Douzdjian V. Donor liver selection. The South Eastern Organ Procurement Foundation Liver Committee. Am Surg. 1998;64:785–790
  190. Fukumori T, Ohkohchi N, Tsukamoto S, Satomi S. Why is fatty liver unsuitable for transplantation? Deterioration of mitochondrial ATP synthesis and sinusoidal structure during cold preservation of a liver with steatosis. Transplant Proc. 1997;29:412–415
  191. Gao W, Connor HD, Lemasters JJ, Mason RP, Thurman RG. Primary nonfunction of fatty livers produced by alcohol is associated with a new antioxidant insensitive free radical species. Transplantation. 1995;59:674–679
  192. Fishbein TM, Fiel MI, Emre S, Cubukcu O, Guy SR, Schwartz ME, et al. Use of livers with microvesicular fat safely expands the donor pool. Transplantation. 1997;64:248–251
  193. McCaughan GW. Recurrence of nonalcoholic steatohepatitis (NASH) post-liver transplantation (letter). Liver Transpl Surg. 1997;3:683
  194. Molloy RM, Komorowski R, Varma RR. Recurrent nonalcoholic steatohepatitis and cirrhosis after liver transplantation. Liver Transpl Surg. 1997;3:177–178
  195. Carson K, Washington MK, Treem WR, Clavien PA, Hunt CM. Recurrence of nonalcoholic steatohepatitis in a liver transplant recipient. Liver Transpl Surg. 1997;3:174–176
  196. Kim WR, Poterucha JJ, Porayko MK, Dickson ER, Steers JL, Wiesner RH. Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation. 1996;62:1802–1805
  197. D'Sauza-Gburek SM, Batts KP, Nikias GA, Weisner RH, Krom RAF. Liver transplantation for jejunoileal bypass-associated cirrhosis. Liver Transpl Surg. 1997;3:23–27
  198. Palmer M, Schaffner F, Thung SN. Excessive weight gain after liver transplantation. Transplantation. 1991;51:797–800
  199. Saadeh S, Younossi ZM. The spectrum of nonalcoholic fatty liver disease: from steatosis to nonalcoholic steatohepatitis. Cleve Clin J Med. 2000;67:96–97 101–104
  200. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology. 1990;99:1408–1413
  201. Anonymous . Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med. 1998;158:1855–1867
  202. Barlow SE, Dietz WH. Obesity evaluation and treatment: expert committee recommendations. The Maternal and Child Health Bureau, Health Resources and Services Administration and the Department of Health and Human Services. Pediatrics. 1998;102:E29
  203. Hermansen K. Diet, blood pressure and hypertension. Br J Nutr. 2000;83(Suppl 1):S113–S119
  204. Sothern MS, Loftin JM, Udall JN, Suskind RM, Ewing TL, Tang SC, et al. Safety, feasibility, and efficacy of a resistance training program in preadolescent obese children. Am J Med Sci. 2000;319:370–375
  205. Tremblay A, Doucet E, Imbeault P. Physical activity and weight maintenance. Int J Obes Relat Metab Disord. 1999;23(suppl 3):S50–S54
  206. Niskanen L, Uusitupa M, Sarlund H, Siitonen O, Paljarvi L, Laakso M. The effects of weight loss on insulin sensitivity, skeletal muscle composition and capillary density in obese non-diabetic subjects. Int J Obes Relat Metab Disord. 1996;20:154–160
  207. Lean ME. Is long-term weight loss possible?. Br J Nutr. 2000;83(Suppl 1):S103–S111
  208. Balkestein EJ, van Aggel-Leijssen DP, van Baak MA, Struijker-Boudier HA, Van Bortel LM. The effect of weight loss with or without exercise training on large artery compliance in healthy obese men. J Hypertens. 1999;17:1831–1835
  209. Weinsier RL, Wilson LJ, Lee J. Medically safe rate of weight loss for the treatment of obesity: a guideline based on risk of gallstone formation. Am J Med. 1995;98:115–117
  210. Shiffman ML, Kaplan GD, Brinkman-Kaplan V, Vickers FF. Prophylaxis against gallstone formation with ursodeoxycholic acid in patients participating in a very-low-calorie diet program. Ann Intern Med. 1995;122:899–905
  211. Sugerman HJ, Brewer WH, Shiffman ML, Brolin RE, Fobi MA, Linner JH, et al  A multicenter, placebo-controlled, randomized, double-blind, prospective trial of prophylactic ursodiol for the prevention of gallstone formation following gastric-bypass-induced rapid weight loss. Am J Surg. 1995;169:91–96 discussion 96–97
  212. Worobetz LJ, Inglis FG, Shaffer EA. The effect of ursodeoxycholic acid therapy on gallstone formation in the morbidly obese during rapid weight loss. Am J Gastroenterol. 1993;88:1705–1710
  213. Broomfield PH, Chopra R, Sheinbaum RC, Bonorris GG, Silverman A, Schoenfield LJ, et al. Effects of ursodeoxycholic acid and aspirin on the formation of lithogenic bile and gallstones during loss of weight. N Engl J Med. 1988;319:1567–1572
  214. Shoheiber O, Biskupiak JE, Nash DB. Estimation of the cost savings resulting from the use of ursodiol for the prevention of gallstones in obese patients undergoing rapid weight reduction. Int J Obes Relat Metab Disord. 1997;21:1038–1045
  215. Anonymous . Weight cycling. National Task Force on the Prevention and Treatment of Obesity. JAMA. 1994;272:1196–1202
  216. Harris RB, Kor H. Insulin insensitivity is rapidly reversed in rats by reducing dietary fat from 40 to 30% of energy. J Nutr. 1992;122:1811–1822
  217. Silberbauer CJ, Jacober B, Langhans W. Dietary fat level and short-term effects of a high-fat meal on food intake and metabolism. Ann Nutr Metab. 1998;42:75–89
  218. Oakes ND, Cooney GJ, Camilleri S, Chisholm DJ, Kraegen EW. Mechanisms of liver and muscle insulin resistance induced by chronic high-fat feeding. Diabetes. 1997;46:1768–1774
  219. Hallfrisch J, Facn , Behall KM. Mechanisms of the effects of grains on insulin and glucose responses. J Am Coll Nutr. 2000;19:320S–325S
  220. Song YJ, Sawamura M, Ikeda K, Igawa S, Yamori Y. Soluble dietary fibre improves insulin sensitivity by increasing muscle GLUT-4 content in stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 2000;27:41–45
  221. Luo J, Rizkalla SW, Boillot J, Alamowitch C, Chaib H, Bruzzo F, et al. Dietary (n-3) polyunsaturated fatty acids improve adipocyte insulin action and glucose metabolism in insulin-resistant rats: relation to membrane fatty acids. J Nutr. 1996;126:1951–1958
  222. Clarke SD, Baillie R, Jump DB, Nakamura MT. Fatty acid regulation of gene expression. Its role in fuel partitioning and insulin resistance. Ann N Y Acad Sci. 1997;827:178–187
  223. Montagne O, Vedel I, Durand-Zaleski I. Assessment of the impact of fibrates and diet on survival and their cost-effectiveness: evidence from randomized, controlled trials in coronary heart disease and health economic evaluations. Clin Ther. 1999;21:2027–2035
  224. Krauss RM, Eckel RH, Howard B, Appel LJ, Daniels SR, Deckelbaum RJ, et al. AHA dietary guidelines: revision 2000. A statement for healthcare professionals from the nutrition committee of the American Heart Association. Stroke. 2000;31:2751–2766
  225. Clark MJ, Sterrett JJ, Carson DS. Diabetes guidelines: a summary and comparison of the recommendations of the American Diabetes Association, Veterans Health Administration, and American Association of Clinical Endocrinologists. Clin Ther. 2000;22:899–910 discussion 898
  226. Miller WC, Koceja DM, Hamilton EJ. A meta-analysis of the past 25 years of weight loss research using diet, exercise or diet plus exercise intervention. Int J Obes Relat Metab Disord. 1997;21:941–947
  227. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr. 1992;56:320–328
  228. Stern JS, Hirsch J, Blair SN, Foreyt JP, Frank A, Kumanyika SK, et al. Weighing the options: criteria for evaluating weight-management programs. The Committee to Develop Criteria for Evaluating the Outcomes of Approaches to Prevent and Treat Obesity. Obes Res. 1995;3:591–604
  229. Howell WH, McNamara DJ, Tosca MA, Smith BT, Gaines JA. Plasma lipid and lipoprotein responses to dietary fat and cholesterol: a meta-analysis. Am J Clin Nutr. 1997;65:1747–1764
  230. Brown SA, Upchurch S, Anding R, Winter M, Ramirez G. Promoting weight loss in type II diabetes. Diabetes Care. 1996;19:613–624
  231. Tang JL, Armitage JM, Lancaster T, Silagy CA, Fowler GH, Neil HA. Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects. BMJ. 1998;316:1213–1220
  232. Kirsch I. Hypnotic enhancement of cognitive-behavioral weight loss treatments—another meta-reanalysis. J Consult Clin Psychol. 1996;64:517–519
  233. Allison DB, Faith MS. Hypnosis as an adjunct to cognitive-behavioral psychotherapy for obesity: a meta-analytic reappraisal. J Consult Clin Psychol. 1996;64:513–516
  234. Petrides AS, Matthews DE, Esser U. Effect of moderate exercise on insulin sensitivity and substrate metabolism during post-exercise recovery in cirrhosis. Hepatology. 1997;26:972–979
  235. Fogelholm M, Kukkonen-Harjula K, Nenonen A, Pasanen M. Effects of walking training on weight maintenance after a very-low-energy diet in premenopausal obese women: a randomized controlled trial. Arch Intern Med. 2000;160:2177–2184
  236. Ross R, Dagnone D, Jones PJ, Smith H, Paddags A, Hudson R, et al. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial. Ann Intern Med. 2000;133:92–103
  237. Blumenthal JA, Sherwood A, Gullette EC, Babyak M, Waugh R, Georgiades A, et al. Exercise and weight loss reduce blood pressure in men and women with mild hypertension: effects on cardiovascular, metabolic, and hemodynamic functioning. Arch Intern Med. 2000;160:1947–1958
  238. Donnelly JE, Jacobsen DJ, Heelan KS, Seip R, Smith S. The effects of 18 months of intermittent vs. continuous exercise on aerobic capacity, body weight and composition, and metabolic fitness in previously sedentary, moderately obese females. Int J Obes Relat Metab Disord. 2000;24:566–572
  239. Andersen RE, Wadden TA, Bartlett SJ, Zemel B, Verde TJ, Franckowiak SC. Effects of lifestyle activity vs structured aerobic exercise in obese women: a randomized trial [see comments]. JAMA. 1999;281:335–340
  240. Weinstock RS, Dai H, Wadden TA. Diet and exercise in the treatment of obesity: effects of 3 interventions on insulin resistance. Arch Intern Med. 1998;158:2477–2483
  241. Bylund AC, Bjuro T, Cederblad G, Holm J, Lundholm K, Sjostroom M, et al. Physical training in man. Skeletal muscle metabolism in relation to muscle morphology and running ability. Eur J Appl Physiol. 1977;36:151–169
  242. Kelley DE, Mandarino LJ. Fuel selection in human skeletal muscle in insulin resistance: a reexamination. Diabetes. 2000;49:677–683
  243. Kang J, Robertson RJ, Hagberg JM, Kelley DE, Goss FL, DaSilva SG, et al. Effect of exercise intensity on glucose and insulin metabolism in obese individuals and obese NIDDM patients. Diabetes Care. 1996;19:341–349
  244. Stefanick ML. Physical activity for preventing and treating obesity-related dyslipoproteinemias. Med Sci Sports Exerc. 1999;31:S609–S618
  245. Eriksson J, Tuominen J, Valle T, Sundberg S, Sovijarvi A, Lindholm H, et al. Aerobic endurance exercise or circuit-type resistance training for individuals with impaired glucose tolerance?. Horm Metab Res. 1998;30:37–41
  246. Newell SA, Bowman JA, Cockburn JD. Can compliance with nonpharmacologic treatments for cardiovascular disease be improved?. Am J Prev Med. 2000;18:253–261
  247. Jakicic JM, Winters C, Lang W, Wing RR. Effects of intermittent exercise and use of home exercise equipment on adherence, weight loss, and fitness in overweight women: a randomized trial. JAMA. 1999;282:1554–1560
  248. Yanovsky SZ, Yanovsky JA. Obesity. N Engl J Med. 2002;346:591–602
  249. Allison TG, Squires RW, Johnson BD, Gau GT. Achieving National Cholesterol Education Program goals for low-density lipoprotein cholesterol in cardiac patients: importance of diet, exercise, weight control, and drug therapy. Mayo Clin Proc. 1999;74:466–473
  250. Fanghanel G, Cortinas L, Sanchez-Reyes L, Berber A. A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity. Int J Obes Relat Metab Disord. 2000;24:144–150
  251. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med. 1999;106:179–184
  252. Cordero-MacIntyre ZR, Peters W, Libanati CR, Espana RC, Howell WH, Lohman TG. Effect of a weight-reduction program on total and regional body composition in obese postmenopausal women. Ann N Y Acad Sci. 2000;904:526–535
  253. Lindgarde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med. 2000;248:245–254
  254. Heymsfield SB, Segal KR, Hauptman J, Lucas CP, Boldrin MN, Rissanen A, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med. 2000;160:1321–1326
  255. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 2000;9:160–167
  256. Hall JC, Watts JM, O'Brien PE, Dunstan RE, Walsh JF, Slavotinek AH, et al. Gastric surgery for morbid obesity. The Adelaide Study. Ann Surg. 1990;211:419–427
  257. Naslund I. Gastric bypass versus gastroplasty. A prospective study of differences in two surgical procedures for morbid obesity. Acta Chir Scand Suppl. 1987;536:1–60
  258. Sugerman HJ, Wolper JL. Failed gastroplasty for morbid obesity. Revised gastroplasty versus Roux-Y gastric bypass. Am J Surg. 1984;148:331–336
  259. Pories WJ, Flickinger EG, Meelheim D, Van Rij AM, Thomas FT. The effectiveness of gastric bypass over gastric partition in morbid obesity: consequence of distal gastric and duodenal exclusion. Ann Surg. 1982;196:389–399
  260. Laws HL, Piantadosi S. Superior gastric reduction procedure for morbid obesity: a prospective, randomized trial. Ann Surg. 1981;193:334–340
  261. Sugerman HJ, Starkey JV, Birkenhauer R. A randomized prospective trial of gastric bypass versus vertical banded gastroplasty for morbid obesity and their effects on sweets versus non-sweets eaters. Ann Surg. 1987;205:613–624
  262. Griffen WO, Young VL, Stevenson CC. A prospective comparison of gastric and jejunoileal bypass procedures for morbid obesity. Ann Surg. 1977;186:500–509
  263. Manco M, Mingrone G, Greco AV, Capristo E, Gniuli D, De Gaetano A, et al. Insulin resistance directly correlates with increased saturated fatty acids in skeletal muscle triglycerides. Metabolism. 2000;49:220–224
  264. Kelley DE, Goodpaster B, Wing RR, Simoneau JA. Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. Am J Physiol. 1999;277:E1130–E1141
  265. Arslanian S, Suprasongsin C. Glucose-fatty acid interactions in prepubertal and pubertal children: effects of lipid infusion. Am J Physiol. 1997;272:E523–E529
  266. Mingrone G, DeGaetano A, Greco AV, Capristo E, Benedetti G, Castagneto M, et al. Reversibility of insulin resistance in obese diabetic patients: role of plasma lipids. Diabetologia. 1997;40:599–605
  267. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose-fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances in diabetes mellitus. Lancet. 1963;1:785–789
  268. Rashid A, Wu TC, Huang CC, Chen CH, Lin HZ, Yang SQ, et al. Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liver. Hepatology. 1999;29:1131–1138
  269. Simoneau JA, Kelley DE, Neverova M, Warden CH. Overexpression of muscle uncoupling protein 2 content in human obesity associates with reduced skeletal muscle lipid utilization. FASEB J. 1998;12:1739–1745
  270. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med. 2000;6:998–1003
  271. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in nonalcoholic steatohepatitis. Lancet. 2001;358:893–894
  272. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol. 2001;96:519–525
  273. Arioglu E, Duncan-Morin J, Sebring N, Rother KI, Gottlieb N, Lieberman J, et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes [see comments]. Ann Intern Med. 2000;133:263–274
  274. Ide T, Nakazawa T, Mochizuki T, Murakami K. Tissue-specific actions of antidiabetic thiazolidinediones on the reduced fatty acid oxidation in skeletal muscle and liver of Zucker diabetic fatty rats. Metabolism. 2000;49:521–525
  275. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis (letter). J Hepatol. 1999;31:384
  276. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study [see comments]. J Pediatr. 2000;136:734–738
  277. Obinata K, Maruyama T, Hayashi M, Watanabe T, Nittono H. Effect of taurine on the fatty liver of children with simple obesity. Adv Exp Med Biol. 1996;403:607–613
  278. Abdelmalek MF, Angulo P, Jorgenson RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: a pilot study. Am J Gastroenterol. 2001;96:2711–2717
  279. Miglio F, Rovati LC, Santoro A, Setnikar I. Efficacy and safety of oral betaine glucuronate in nonalcoholic steatohepatitis. A double-blind, randomized, parallel-group, placebo-controlled prospective clinical study. Arzneimittelforschung. 2000;50:722–727
  280. Garcia-Monzon C, Martin-Perez E, Iacono OL, Fernandez-Bermejo M, Majano PL, Apolinario A, et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol. 2000;33:716–724

☆ Address requests for reprints to: Chair, Clinical Practice Committee, AGA National Office, c/o Membership Department, 7910 Woodmont Avenue, 7th Floor, Bethesda, Maryland 20814. Fax: (301) 654-5920.

☆☆ This literature review and the recommendations therein were prepared for the American Gastroenterological Association (AGA) Clinical Practice Committee and the American Association for the Study of Liver Diseases (AASLD) Practice Guidelines Committee. The paper was approved by the Clinical Practice Committee on March 3, 2002, and by the AGA Governing Board on May 19, 2002. It was approved by the AASLD Governing Board and AASLD Practice Guidelines Committee on May 24, 2002.

PII: S0016-5085(02)00304-9

Gastroenterology
Volume 123, Issue 5 , Pages 1705-1725 , November 2002

Article Tools

* Image Usage & Resolution